Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Certoparin→

Certoparin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9005-49-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Low-molecular-weight heparin (LMWH)antithrombin-dependent anticoagulant
Mechanism of action
Binds antithrombin and accelerates inhibition of coagulation factor Xa, with less activity against thrombin (factor IIa) than unfractionated heparin, reducing fibrin formation and thrombus propagation.
Indications / reported uses
  • Prevention of venous thromboembolism in surgical and selected medical patients at risk, and treatment of thromboembolic conditions in countries where certoparin is authorised; product-specific dosing and availability apply

Sources: NLM MeSH — Certoparin · PubMed — Certoparin low-molecular-weight heparin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Certoparin Environmental Risk Assessment (ERA) (the Certoparin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.